Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014) - Nitz, U.; Gluz, O.; Huober, J.; Kreipe, H. H.; Kates, R. E.; Hartmann, Arndt; Erber, Ramona; Moustafa, Z.; Scholz, M.; Lisboa, B.; Mohrmann, S.; Moebus, V.; et al. (Annals of Oncology, 2017)
EVALuna2:34898